Tirzepatide Dosage and Protocols
Tirzepatide dosage protocols reported in published research, plus reconstitution and storage.
Dose-Proportional Exposure Across the Therapeutic Range
Tirzepatide exhibits predictable, dose-proportional pharmacokinetics across its 5 mg, 10 mg, and 15 mg dose levels, supporting the 4-week dose escalation strategy used in clinical practice. • Exposure increases proportionally with dose from 5 mg through 15 mg, allowing predictable efficacy scaling during the titration period. • Steady-state concentrations are achieved by week 4-5 of each dose level, which informs the recommended 4-week minimum at each dose before escalation. • The 39-amino acid peptide is built on a GIP backbone (not GLP-1), with approximately 5-fold higher affinity for the GIP receptor than native GIP and reduced but clinically meaningful affinity for the GLP-1 receptor.
Dosing Summary
Dosing details above reflect FDA-approved labeling and/or published clinical protocols. Always refer to the official drug label (linked above) for approved prescribing details, contraindications, and warnings.
Reported protocol doses
Reconstitution
A 10mg vial with 2mL of bacteriostatic water is the pairing reported most often. 10mg vial + 2mL bacteriostatic water = 5mg/mL. Start at 2.5mg (0.5mL / 50 units) weekly and titrate per protocol.
Work out your own concentration with the reconstitution calculator.
Doses shown are those reported in published research, not a recommendation.
References
- Tirzepatide Once Weekly for the Treatment of Obesity · Jastreboff AM, et al. · 2022
- Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503-515. · Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K · 2021
- Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. · Nicholls SJ, Bhatt DL, Buse JB et al. · 2024
- Tirzepatide - StatPearls - NCBI Bookshelf
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. · Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A · 2022
- Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. · Nicholls SJ, Pavo I, Bhatt DL et al. · 2025